Supernus raises $350M in convertible senior notes

Neurology company Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) raised $350 million through the sale of 0.625% convertible senior notes due 2023. The notes have an initial conversion price of about $59.33. The price is a 32% premium to Supernus' close of $44.90 on March 13, when it proposed the offering after market close...